C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/12 (2006.01) A61K 31/4025 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2667372
Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
L'invention concerne des composés et des compositions pharmaceutiques de formule (I) par blocage des récepteurs CB1 via un mécanisme d'agonisme inverse qui sont utiles pour réduire la masse corporelle chez les mammifères, le trouble cognitif associé à la schizophrénie, atténuer la prise de poids liée au traitement observée pendant un traitement avec des antipsychotiques et ont une biodisponibilité accrue.
Coffey David Scott
Hu Jingdan
Keding Stacy Jo
Krushinski Joseph Herman Junior
Schaus John Mehnert
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1611009